Stock of the Day

March 17, 2022

Lipocine (LPCN)

$2.23
-$0.06 (-2.6%)
Market Cap: $18.88M

About Lipocine

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Today's Trend

Lipocine Inc. (NASDAQ: LPCN) is trading higher today. The most likely near-term catalyst is heavy insider buying (CEO and a director increased their stakes), which has driven volume well above recent averages and provided buy-side momentum. Offsetting this: mixed analyst notes from HC Wainwright (model upgrades but a neutral stance and some press suggesting a downgrade) and an active shareholder litigation inquiry, which add uncertainty for investors.

  • Director John W. Higuchi purchased 40,000 shares at ~$2.03 (SEC-filed), increasing his stake materially — a strong signal of insider confidence that likely supported the stock’s intraday strength. Director John Higuchi Buys $81,200 in Lipocine Stock
  • CEO Mahesh Patel bought 25,000 shares at about $2.03, raising his holding nearly 18% — another direct insider purchase that may attract momentum buyers in a low-float, small-cap stock. Mahesh Patel Purchases 25,000 Shares
  • HC Wainwright raised FY2026 and quarterly EPS estimates (narrowing projected losses) but maintained a "Neutral" rating — supportive to fundamentals but not a bullish analyst upgrade. HC Wainwright Neutral Rating and Estimates Update
  • Lipocine’s recent quarter beat revenue and posted a smaller-than-expected EPS loss, which underpins the revised sell-side models but the company remains cash-consuming and loss-making. MarketBeat LPCN financial summary
  • Press coverage showed HC Wainwright language that could be interpreted as more cautious/downgrade-focused — any negative wording from a healthcare specialist can trigger short-term selling in thinly traded names. MSN: HC Wainwright Downgrades Coverage
  • Shareholder litigation inquiry announced by Johnson Fistel introduces legal risk and potential expense — a downside catalyst that can weigh on sentiment and valuation. Johnson Fistel Investigation Announcement

Bottom line for investors: insider purchases are the immediate bullish driver; however, analyst caution and legal exposure mean the move may be volatile and short-lived unless accompanied by clearer operational progress or further positive analyst action.

← Previous Stock of the DayNext Stock of the Day →